CNSX:VP Vodis Pharmaceuticals (VP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Vodis Pharmaceuticals Stock (CNSX:VP) Get Vodis Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume51,582 shsAverage Volume1,714 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vodis Pharmaceuticals Inc. operates as an application stage company for producing medical marijuana. It operates in Canada and the United States. The company is based in Delta, Canada. Read More Receive VP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vodis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VP Stock News HeadlinesVP debate 'spin room' scene: Talking points and unscripted momentsOctober 22, 2024 | usatoday.comVice President Harris in ‘Excellent Health,’ Medical Report StatesOctober 14, 2024 | msn.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 10 at 1:00 AM | Porter & Company (Ad)Vance Confident, Walz Uneven in VP Debate Heavy on PolicyOctober 2, 2024 | wsj.comRead the full VP debate transcript from the Walz-Vance showdownOctober 2, 2024 | cbsnews.comAs Investigations Swirl, Another Adams Official ResignsSeptember 24, 2024 | nytimes.comTonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial OperationsSeptember 10, 2024 | markets.businessinsider.comKalVista Pharma Appoints Brian Piekos As New CFOSeptember 10, 2024 | markets.businessinsider.comSee More Headlines VP Stock Analysis - Frequently Asked Questions How do I buy shares of Vodis Pharmaceuticals? Shares of VP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vodis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vodis Pharmaceuticals investors own include Ampliphi Biosciences (APHB), Apellis Pharmaceuticals (APLS), Athersys (ATHX), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS) and Aurora Cannabis (ACBFF). Industry, Sector and Symbol Stock ExchangeCNSX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCNSX:VP CIKN/A Webvodis.ca Phone778-990-8985FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (CNSX:VP) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersOpenAI is preparing to go publicOpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredImportant SpaceX PREDICTIONThe biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian s...Banyan Hill Publishing | SponsoredHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vodis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vodis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.